Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 4:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 110 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo for Aspirin Clear all
Completed Phase 4 Interventional Results available

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention

NCT02270242
View directory record Official record
Conditions
Cardiovascular Disease, Interventional Cardiology
Interventions
Aspirin, Placebo, ticagrelor
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
9,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Sep 23, 2026, 4:31 AM EDT
Recruiting Phase 4 Interventional

Treatment With Aspirin After Preeclampsia: TAP Trial

NCT06281665
View directory record Official record
Conditions
Hypertensive Disorder of Pregnancy, Pre-Eclampsia, Hypertension, Eclampsia, Gestational Hypertension, Cardiovascular Diseases, Toxemia, Pregnancy Complications, Vascular Diseases, Hypertension, Pregnancy Induced, Hypertension;Pre-Eclamptic
Interventions
Low-dose aspirin, Placebo
Drug
Lead sponsor
Malamo Countouris
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin

NCT00630877
View directory record Official record
Conditions
Dyslipidemia
Interventions
Niacin extended-release (NER), Niacin extended-release (NER) placebo, Aspirin (ASA), Aspirin (ASA) placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
40
States / cities
Birmingham, Alabama • Anaheim, California • Walnut Creek, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2009 · Synced Sep 23, 2026, 4:31 AM EDT
Terminated Phase 4 Interventional Results available

Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine

NCT01629329
View directory record Official record
Conditions
Migraine Headaches
Interventions
Aspirin, Acetaminophen, Caffeine pills, Prochlorperazine 10mg
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Results available

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)

NCT01597375
View directory record Official record
Conditions
Asthma, Aspirin-Induced, Aspirin Exacerbated Asthma
Interventions
Placebo Oral Tablet, Prasugrel Oral Tablet
Drug
Lead sponsor
Elliot Israel, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 3 Interventional Results available

Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)

NCT00065806
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Atorvastatin, Placebo atorvastatin
Drug
Lead sponsor
Laura Schanberg
Other
Eligibility
10 Years to 21 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Sep 23, 2026, 4:31 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

COMT on Aspirin Platelets Effects (CAPE)

NCT03433586
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Aspirin 81 mg, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dupilumab for Aspirin-exacerbated Respiratory Disease

NCT03595488
View directory record Official record
Conditions
Aspirin-exacerbated Respiratory Disease
Interventions
Dupilumab
Drug
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches

NCT02176655
View directory record Official record
Conditions
Delayed Alcohol Induced Headache
Interventions
VVD-101, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Mountain View, California • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 4 Interventional

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

NCT05009862
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Rivaroxaban 2.5 Mg Oral Tablet, Placebo, Aspirin 81Mg Ec Tab
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 3 Interventional Results available

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

NCT01776424
View directory record Official record
Conditions
Prevention & Control
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Aspirin placebo, Rivaroxaban placebo, Pantoprazole, Pantoprazole placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
27,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
53
States / cities
Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2022 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers

NCT02123849
View directory record Official record
Conditions
Lung Carcinoma, Tobacco Use Disorder
Interventions
Aspirin, Laboratory Biomarker Analysis, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
2
States / cities
Tucson, Arizona • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Results available

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)

NCT03028350
View directory record Official record
Conditions
Asthma, Aspirin-Induced
Interventions
Ifetroban Oral Capsule, Placebo Oral Capsule
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
16
States / cities
Tucson, Arizona • Lancaster, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 23, 2026, 4:31 AM EDT
Terminated Phase 2 Interventional Results available

Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma

NCT00790452
View directory record Official record
Conditions
Glioblastoma
Interventions
Aspirin, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Anti-Platelets in Chronic Obstructive Pulmonary Disease

NCT05567562
View directory record Official record
Conditions
COPD, Emphysema, Emphysema or COPD
Interventions
dual anti-platelet therapy, Placebo
Combination Product · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old

NCT04122170
View directory record Official record
Conditions
Healthy
Interventions
Ticagrelor Oral Tablet - Pre-Treatment, Aspirin (ASA) Oral Tablet - Pre-Treatment, Bentracimab (PB2452) Infusion, Placebo (0.9% Sodium chloride) infusion
Drug
Lead sponsor
SFJ Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
13
States / cities
Rogers, Arkansas • Cypress, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Sep 23, 2026, 4:31 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation

NCT02521285
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Adenocarcinoma
Interventions
Aspirin, Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PACT (Platelet Activity After Clopidogrel Termination)

NCT00619073
View directory record Official record
Conditions
Blood Platelets, Clopidogrel
Interventions
clopidogrel + aspirin, placebo, Aspirin
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
21 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Results available

Modulation of Immune Activation by Aspirin

NCT02155985
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Aspirin, Placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 3 Interventional Results available

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

NCT02239120
View directory record Official record
Conditions
Stroke, Secondary Prevention
Interventions
optional ASA as comedication, placebo to ASA, placebo to optional ASA as comedication, placebo to dabigatran etexilate, ASA 100 mg, dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 150 Years
Enrollment
5,390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
110
States / cities
Phoenix, Arizona • Beverly Hills, California • El Cajon, California + 94 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of DHA on Periodontitis

NCT01976806
View directory record Official record
Conditions
Periodontitis, Gingivitis, Inflammation
Interventions
Aspirin, Docosahexaenoic acid, Placebo (for Docosahexaenoic acid)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Results available

Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease

NCT02216357
View directory record Official record
Conditions
Aspirin Exacerbated Respiratory Disease (AERD)
Interventions
Ifetroban, Oral Capsule, Placebo, Oral Capsule
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
San Diego, California • Overland Park, Kansas • West Nyack, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease

NCT00841789
View directory record Official record
Conditions
Mucocutaneous Lymph Node Syndrome, Kawasaki Disease
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Michael Portman
Other
Eligibility
2 Months to 20 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
7
States / cities
New Hyde Park, New York • New York, New York • The Bronx, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4

NCT03844191
View directory record Official record
Conditions
Coronary Disease
Interventions
RUC-4 Compound
Drug
Lead sponsor
CeleCor Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 23, 2026, 4:31 AM EDT